New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab

Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC.

Automated summary

Our study aimed to analyze changes in ocular surface before and after 4 months of dupilumab treatment in severe AD patients. The results showed that all 25 patients had ocular surface alterations prior to dupilumab treatment, and there is a possibility of worsened clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC caused by dupilumab.